Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.

Bioorganic & medicinal chemistry letters - 1 Oct 2014

Göring Stefan, Taymans Jean-Marc, Baekelandt Veerle, Schmidt Boris

Abstract excerpt

The most prevalent leucine-rich repeat kinase 2 (LRRK2) mutation G2019S is associated with Parkinson's disease (PD). It enhances kinase activity and has been identified in both familial and sporadic cases. Kinase activity was reported to be required for LRRK2 mutants to exert their toxic effects....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hydrogen Bonding
Share to Indoles
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Structure

Share to Protein Kinase Inhibitors

Share to Structure-Activity Relationship

Share to Zebrafish

Share to Zebrafish Proteins

Source

Identifiers

PMID: 25219901
DOI: 10.1016/j.bmcl.2014.08.049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25219901-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.PMID 25219901Read ↗

Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain.Semantic proximity Read ↗

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.Semantic proximity Read ↗

Structure-Based Virtual Screening and De Novo Design to Identify Submicromolar Inhibitors of G2019S Mutant of Leucine-Rich Repeat Kinase 2.Semantic proximity Read ↗

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.Semantic proximity Read ↗

GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor.Semantic proximity Read ↗

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.Semantic proximity Read ↗

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read ↗

Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease.Semantic proximity Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Semantic proximity Read ↗

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.